Decoy Therapeutics Inc.
Decoy Therapeutics Inc. (DCOY): 5 pipeline candidates · 57 upcoming catalysts · ~8 mo cash runway. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
8.3 months
D/E 1.17 · 0% dilution
Lead: Approved
5 candidates
57 upcoming, next in ~42d
0 buys · 2 sells (180d)
A transparent, data-derived signal for Decoy Therapeutics Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$3.4M
Cash
$7.8M
Quarterly Burn
$2.9M
Runway
8.3 mo
Revenue
—
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (5 candidates)
| Drug | Phase |
|---|---|
| chemical entity | Approved |
| cov | Preclinical |
| seclidemstat | Phase 2 |
| sp-3164 | Preclinical |
| tri | Preclinical |
Upcoming Catalysts (57)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
1
Total value held
$7
| Holder | Shares | Value |
|---|---|---|
| morgan stanley | 1 | $7 |
Frequently asked questions
How many drug candidates are in Decoy Therapeutics Inc.'s pipeline?
Decoy Therapeutics Inc. (DCOY) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Decoy Therapeutics Inc.'s lead drug candidate?
Decoy Therapeutics Inc.'s most advanced tracked candidate is chemical entity (Approved) for hospitalized COVID-19 patients.
What is Decoy Therapeutics Inc.'s next catalyst?
Decoy Therapeutics Inc.'s next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: OMEGAVEN" — expected July 30, 2026.
What is Decoy Therapeutics Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Decoy Therapeutics Inc. has approximately 8.3 months of cash runway.
What is Decoy Therapeutics Inc.'s market capitalization?
Decoy Therapeutics Inc.'s market capitalization is approximately $3.4M.
Get the full picture on Decoy Therapeutics Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.